Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4

Figure 1

Tamoxifen-resistant cells were constructed based on parental cells with tamoxifen treatment. CCK-8 test was performed to identify the vitality of acquired tamoxifen-resistant breast cancer cell lines (MCF7/TR and T47D/TR) and their parental cell lines (MCF7 and T47D). Cells were treated with the indicated tamoxifen dose for 72 h (data are represented as mean ± S.D of triplicate experiments;  < 0.05).